公开(公告)号：US20210393775A1

公开(公告)日：2021-12-23

申请号：US17343150

申请日：2021-06-09

Applicant: Janssen Biotech, Inc.

Inventor： Ming Qi

IPC: A61K39/395 ,  A61K38/47 ,  A61K31/573 ,  A61K31/69 ,  A61K31/198 ,  A61K31/454 ,  A61P35/00

Abstract: The present invention relates to methods of treating multiple myeloma using an approved drug product comprising daratumumab and hyaluronidase. Also described are drug products containing daratumumab and hyaluronidase, and methods of selling or offering for sale a drug product comprising daratumumab and hyaluronidase.

公开(公告)号：US20200308296A1

公开(公告)日：2020-10-01

申请号：US16830585

申请日：2020-03-26

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: C07K16/28 ,  A61K38/47 ,  A61K31/454 ,  A61K31/573 ,  A61K47/26 ,  A61K47/22 ,  A61K47/18 ,  A61P35/00

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with pomalidomide and dexamethasone.

公开(公告)号：US20190127479A1

公开(公告)日：2019-05-02

申请号：US16177239

申请日：2018-10-31

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K9/00 ,  A61K39/395

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

公开(公告)号：US20230348615A1

公开(公告)日：2023-11-02

申请号：US18348384

申请日：2023-07-07

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: C07K16/28 ,  A61K38/47 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00 ,  C12N9/24 ,  A61K47/10

CPC classification number: C07K16/2896 ,  A61K38/47 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00 ,  C12N9/2402 ,  A61K47/10 ,  A61K45/06

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and their uses.

公开(公告)号：US20230277660A1

公开(公告)日：2023-09-07

申请号：US18300183

申请日：2023-04-13

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: A61K39/395 ,  A61K38/47 ,  A61K9/00 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K9/0053 ,  A61K38/47 ,  A61P35/00 ,  C12Y302/01035 ,  A61K2039/545

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib, melphalan and prednisone.

公开(公告)号：US20200316197A1

公开(公告)日：2020-10-08

申请号：US16830810

申请日：2020-03-26

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: A61K39/395 ,  A61K38/47 ,  A61K9/00 ,  A61P35/00 ,  A61K31/69 ,  A61K31/573

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with bortezomib and dexamethasone.

公开(公告)号：US20200308284A1

公开(公告)日：2020-10-01

申请号：US16830763

申请日：2020-03-26

Applicant: Janssen Biotech, Inc.

Inventor： Rajesh Bandekar ,  Pamela Clemens ,  Christoph Heuck ,  Ming Qi ,  Zhilong Yuan

IPC: C07K16/28 ,  A61K47/26 ,  A61K47/18 ,  A61K31/573 ,  A61K31/454 ,  A61P35/00

Abstract: The present invention relates to clinically proven subcutaneous pharmaceutical compositions comprising anti-CD38 antibodies and methods of their uses in combination with lenalidomide and dexamethasone.

公开(公告)号：US20200268847A1

公开(公告)日：2020-08-27

申请号：US16797301

申请日：2020-02-21

Applicant: Janssen Biotech, Inc.

Inventor： Ming Qi

IPC: A61K38/17 ,  A61K31/573 ,  A61K31/454 ,  A61P35/00

Abstract: Disclosed herein are methods of treating multiple myeloma using an antibody that specifically binds CD38 in combination with lenalidomide and dexamethasone.